1-[4-(三氟甲基)-2-嘧啶]-4-哌啶羧酸 | 465514-39-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-[4-(三氟甲基)-2-嘧啶]-4-哌啶羧酸
• 英文名称: 1-(4-(trifluoromethyl)pyrimidin-2-yl)piperidine-4-carboxylic acid
• 英文别名: 1-(4-trifluoromethylpyrimidin-2-yl)-piperidine-4-carboxylic acid；1-[4-(trifluoromethyl)pyrimidin-2-yl]piperidine-4-carboxylic Acid
• CAS: 465514-39-0
• 化学式: C₁₁H₁₂F₃N₃O₂
• mdl: MFCD02091615
• 分子量: 275.23
• InChiKey: QYAIISDWPUEPHG-UHFFFAOYSA-N

物化性质

• 熔点：
  140 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  66.3
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-[4-(三氟甲基)-2-嘧啶]-4-哌啶羧酸 、 对氨基苯酚 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.5h， 以52%的产率得到N-(4-hydroxyphenyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)piperidine-4-carboxamide
  参考文献：
  名称：

  TRPV1 modulators: Synthesis and in vitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives

  摘要：

  A series of new 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives was synthesized and evaluated as TRPV1 modulators in a Ca2+ channel assay in HEK-293 cells overexpressing the human recombinant TRPV1 channel. Structural variations in the putative key portions of the molecules afforded several compounds endowed with agonist and/or antagonist/desensitizing activity at low micromolar concentration. As promising examples from this series, the piperidine-3-carboxamide derivative 31 exerts agonist/desensitizing activity at low micromolar concentration, while piperazinylurea derivatives 39 and 41 act as antagonists with sub-micromolar potency. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.05.041

文献信息

• [EN] PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS<br/>[FR] DERIVES CARBOXAMIDES DE PIPERIDINE/CYCLOHEXANE DESTINES A ETRE UTILISES COMME MODULATEURS DU RECEPTEUR VANILLOIDE
  申请人：GLAXO GROUP LTD

  公开号：WO2005016915A1

  公开（公告）日：2005-02-24

  Certain compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, P, P', X, m and n are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine, as vanilloid receptor modulators.

  某些式（I）化合物，或其药学上可接受的盐或溶剂合物，其中R1、R2、P、P'、X、m和n如说明书中所定义，制备此类化合物的方法，包含此类化合物的药物组合物，以及此类化合物在医学中作为香草素受体调节剂的用途。
• [EN] INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] INHIBITEURS D'ARGINASE ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：MARS INC

  公开号：WO2011133653A1

  公开（公告）日：2011-10-27

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity : Formule (I), (II) where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据式I和式II，化合物是Arginase I和II活性的强效抑制剂：式(I)，(II)中的R1、R2、R3、R4、R5、R6、R7、R8、R9、D、M、X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们用于治疗或预防与Arginase活性相关的疾病或病况的方法。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20100286126A1

  公开（公告）日：2010-11-11

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

  化合物的公式（I）或其立体异构体或药用可接受的盐，以及它们的制备和用途作为药物，其中R1、R2和R3如本文所定义。
• Biologically active compounds
  申请人：Quibell Martin

  公开号：US20060100431A1

  公开（公告）日：2006-05-11

  Compounds of general formula (I) wherein Z=CR 3 R 4 , where R 3 and R 4 are independently chosen from C 0-7 -alkyl P 1 =CR 5 R 6 , P 2 =O, CR 7 R 8 or NR 9 , Y=CR 10 R 11 —C(O) or CR 10 R 11 —C(S) or CR 10 R 11 —S(O) or CR 10 R 11 —SO 2 (X) 0 =.CR 16 R 17 (W) n =0 , S, C(O), S(O) or S(O) 2 — or NR 18 (V) m =C(O), C(S), S(O), S(O) 2 , S(O) 2 NH, OC(O), NHC(O), NHS(O), NHS(O) 2 , OC(O)NH, C(O)NH or CR 19 R 20 , C═N—C(O)—OR 19 or C═N═C(O)—NHR 19 , U=a stable. 5- to 7 membered monocyclic or a stable 8- to 11-membered bicyclic ring which is either saturated or unsaturated, and which includes zero to four heteroatoms and their sales, hydrates, solvates, complexes and prodruges are inhibitors of cathepsin K and other cysteine protease inhibitors and are useful as therapeutic agents, for example in osteoporosis, Paget's disease gingival diseases such as gingivitis and periodontis, hypercalaemia of malignancy, metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthitis and rheumatoid arthritis and neoplastic diseases. The compounds are also useful for validating therapeutic target compounds.

  通式(I)的化合物，其中Z=CR3R4，其中R3和R4独立地选择自C0-7烷基；P1=CR5R6，P2=O，CR7R8或NR9；Y=CR10R11—C（O）或CR10R11—C（S）或CR10R11—S（O）或CR10R11—SO2（X）0=.CR16R17（W）n=0、S、C（O）、S（O）或S（O）2—或NR18（V）m=C（O）、C（S）、S（O）、S（O）2、S（O）2NH、OC（O）、NHC（O）、NHS（O）2、OC（O）NH、C（O）NH或CR19R20、C═N—C（O）—OR19或C═N═C（O）—NHR19；U=稳定的5-至7-成员单环或稳定的8-至11-成员双环，它可以是饱和或不饱和，并且可以包含零到四个杂原子，以及它们的盐、水合物、溶剂合物、配合物和前药是猫hepsin K和其他半胱氨酸蛋白酶抑制剂，可用作治疗剂，例如在骨质疏松症、帕吉特病、牙龈疾病如牙龈炎和牙周炎、恶性高钙血症、代谢性骨病、涉及基质或软骨降解的疾病，特别是骨关节炎和类风湿性关节炎和肿瘤性疾病。这些化合物也可用于验证治疗靶点化合物。
• Tetrahydro-naphthalene and urea derivatives
  申请人：Bouchon Axel

  公开号：US20070167458A1

  公开（公告）日：2007-07-19

  This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q 1a , Q 2a , Q 3a and Q 4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q 1b , Q 2b , Q 3b , Q 4b , Q 5b , R 1b , na, ma, X a and R a are defined.

  本发明涉及一种羟基四氢萘或脲衍生物公式(I)及其盐，其可用作制药制剂的活性成分，其中A代表公式(II)或(III)，其中#代表连接到分子的位置，Q1a、Q2a、Q3a和Q4a被定义；E代表公式(IV)或(V)，其中#代表连接到分子的位置，Q1b、Q2b、Q3b、Q4b、Q5b、R1b、na、ma、Xa和Ra被定义。